PE20020591A1 - Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-[3-(4-pirrolidin-1-ilbutil) ureido] isotiazol-4-carboxilico y metodo de produccion - Google Patents
Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-[3-(4-pirrolidin-1-ilbutil) ureido] isotiazol-4-carboxilico y metodo de produccionInfo
- Publication number
- PE20020591A1 PE20020591A1 PE2001001179A PE2001001179A PE20020591A1 PE 20020591 A1 PE20020591 A1 PE 20020591A1 PE 2001001179 A PE2001001179 A PE 2001001179A PE 2001001179 A PE2001001179 A PE 2001001179A PE 20020591 A1 PE20020591 A1 PE 20020591A1
- Authority
- PE
- Peru
- Prior art keywords
- isothiazole
- benzyloxy
- difluoro
- bromo
- ilbutyl
- Prior art date
Links
- -1 4-BROMO-2,6-DIFLUORO-BENZYLOXY Chemical class 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000007945 N-acyl ureas Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
- 229950004288 tosilate Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A LA SAL HIDROBROMURO O HEMICITRATO O ACETATO, O p-TOSILATO O L-TARTRATO O HEMISUCCINATO DE AMIDA DE ACIDO 3-(4-BROMO-2,6-DIFLUORO-BENCILOXI)-5-[3-(4-PIRROLIDIN-1-ILBUTIL)UREIDO]ISOTIAZOL-4-CARBOXILICO QUE SE CARACTERIZA POR SU PATRON DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A UN METODO PARA PREPARAR LA SAL QUE COMPRENDE MEZCLAR EL ACIDO CON EL COMPUESTO RESPECTIVAMENTE. EL COMPUESTO PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS COMO CANCER CEREBRAL, EPIDERMOIDE, DE VEJIGA, GASTRICO, PANCREATICO, DE MAMA, DE CABEZA, DE CUELLO, ESOFAGAL, DE PROSTATA, COLORECTAL, DE PULMON, RENAL, RINON, OVARICO, GINECOLOGICO, DE TIROIDES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25351300P | 2000-11-28 | 2000-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020591A1 true PE20020591A1 (es) | 2002-07-06 |
Family
ID=22960587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001179A PE20020591A1 (es) | 2000-11-28 | 2001-11-26 | Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-[3-(4-pirrolidin-1-ilbutil) ureido] isotiazol-4-carboxilico y metodo de produccion |
Country Status (49)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
| ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| AU2003281664A1 (en) * | 2002-07-25 | 2004-02-16 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
| KR100668539B1 (ko) * | 2002-08-19 | 2007-01-16 | 화이자 프로덕츠 인크. | 과증식성 질환에 대한 조합요법 |
| ES2288694T3 (es) | 2003-05-20 | 2008-01-16 | Bayer Pharmaceuticals Corporation | Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas. |
| KR101139557B1 (ko) | 2003-07-23 | 2012-04-30 | 바이엘 파마슈티칼스 코포레이션 | 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아 |
| AU2004287416C1 (en) * | 2003-10-27 | 2010-09-09 | Merck Sharp & Dohme Corp. | CCR-2 antagonist salt |
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| WO2005102327A1 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Dosage forms and methods of treatment using vegfr inhibitors |
| MXPA06012394A (es) | 2004-04-30 | 2007-01-31 | Bayer Pharmaceuticals Corp | Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer. |
| TW200538104A (en) * | 2004-05-17 | 2005-12-01 | Pfizer Prod Inc | Phenyl derivatives for the treatment of abnormal cell growth |
| US7550598B2 (en) | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| ATE540941T1 (de) | 2006-06-16 | 2012-01-15 | Lundbeck & Co As H | 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen |
| US7932390B2 (en) | 2006-06-29 | 2011-04-26 | Hoffman-La Roche Inc. | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives |
| GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
| MX2010001636A (es) | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos. |
| WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
| EP3696195B1 (en) | 2010-07-23 | 2024-02-14 | Trustees of Boston University | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
| EP3520773A1 (en) | 2013-03-14 | 2019-08-07 | PanOptica, Inc. | Ocular formulations for drug-delivery to the posterior segment of the eye |
| ES3010497T3 (en) * | 2014-09-17 | 2025-04-03 | Panoptica Inc | Ocular formulations for drug-delivery and protection of the anterior segment of the eye |
| KR20250121146A (ko) * | 2022-12-28 | 2025-08-11 | 비양 테라퓨틱스 컴퍼니 리미티드 | 단백질 티로신 키나제 억제제 및 이의 의약적 용도 |
| WO2026002126A1 (zh) * | 2024-06-27 | 2026-01-02 | 苏州必扬医药科技有限公司 | 一种蛋白酪氨酸激酶抑制剂及其眼用制剂 |
| WO2026002133A1 (zh) * | 2024-06-27 | 2026-01-02 | 苏州必扬医药科技有限公司 | 一种蛋白酪氨酸激酶抑制剂的盐型 |
| WO2026002142A1 (zh) * | 2024-06-27 | 2026-01-02 | 苏州必扬医药科技有限公司 | 一种蛋白酪氨酸激酶抑制剂的半琥珀酸盐晶型 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
-
2001
- 2001-11-19 MX MXPA03004714A patent/MXPA03004714A/es active IP Right Grant
- 2001-11-19 SK SK586-2003A patent/SK5862003A3/sk unknown
- 2001-11-19 EP EP01982663A patent/EP1337521B1/en not_active Expired - Lifetime
- 2001-11-19 HU HU0302553A patent/HUP0302553A3/hu unknown
- 2001-11-19 PT PT01982663T patent/PT1337521E/pt unknown
- 2001-11-19 BR BR0115621-7A patent/BR0115621A/pt not_active Application Discontinuation
- 2001-11-19 YU YU36403A patent/YU36403A/sh unknown
- 2001-11-19 CA CA002430065A patent/CA2430065C/en not_active Expired - Lifetime
- 2001-11-19 AT AT01982663T patent/ATE340786T1/de not_active IP Right Cessation
- 2001-11-19 EE EEP200300247A patent/EE200300247A/xx unknown
- 2001-11-19 AP APAP/P/2001/002358A patent/AP2001002358A0/en unknown
- 2001-11-19 IL IL15537101A patent/IL155371A0/xx unknown
- 2001-11-19 CN CNB018193285A patent/CN1231474C/zh not_active Expired - Fee Related
- 2001-11-19 EA EA200300424A patent/EA005859B1/ru not_active IP Right Cessation
- 2001-11-19 KR KR10-2003-7007057A patent/KR20030059275A/ko not_active Ceased
- 2001-11-19 DO DO2001000288A patent/DOP2001000288A/es unknown
- 2001-11-19 AU AU1420402A patent/AU1420402A/xx active Pending
- 2001-11-19 SI SI200130630T patent/SI1337521T1/sl unknown
- 2001-11-19 CZ CZ20031315A patent/CZ20031315A3/cs unknown
- 2001-11-19 AU AU2002214204A patent/AU2002214204B2/en not_active Ceased
- 2001-11-19 GE GE5216A patent/GEP20053652B/en unknown
- 2001-11-19 ES ES01982663T patent/ES2271086T3/es not_active Expired - Lifetime
- 2001-11-19 KR KR1020057022534A patent/KR20050116401A/ko not_active Abandoned
- 2001-11-19 OA OA1200300137A patent/OA12532A/en unknown
- 2001-11-19 NZ NZ525788A patent/NZ525788A/en unknown
- 2001-11-19 DE DE60123461T patent/DE60123461T2/de not_active Expired - Lifetime
- 2001-11-19 HR HR20030408A patent/HRP20030408A2/hr not_active Application Discontinuation
- 2001-11-19 WO PCT/IB2001/002193 patent/WO2002044158A1/en not_active Ceased
- 2001-11-19 PL PL01362079A patent/PL362079A1/xx not_active Application Discontinuation
- 2001-11-19 DK DK01982663T patent/DK1337521T3/da active
- 2001-11-19 UA UA2003054858A patent/UA74221C2/uk unknown
- 2001-11-19 JP JP2002546528A patent/JP2004514714A/ja not_active Withdrawn
- 2001-11-26 MY MYPI20015382A patent/MY136686A/en unknown
- 2001-11-26 AR ARP010105484A patent/AR031512A1/es not_active Application Discontinuation
- 2001-11-26 PE PE2001001179A patent/PE20020591A1/es not_active Application Discontinuation
- 2001-11-26 UY UY27039A patent/UY27039A1/es not_active Application Discontinuation
- 2001-11-27 TW TW090129315A patent/TWI287542B/zh active
- 2001-11-27 US US09/993,640 patent/US6831091B2/en not_active Expired - Lifetime
- 2001-11-27 PA PA20018533801A patent/PA8533801A1/es unknown
- 2001-11-27 TN TNTNSN01167A patent/TNSN01167A1/fr unknown
- 2001-11-27 SV SV2001000748A patent/SV2002000748A/es unknown
- 2001-11-27 HN HN2001000268A patent/HN2001000268A/es unknown
- 2001-11-27 GT GT200100237A patent/GT200100237A/es unknown
-
2003
- 2003-04-14 IS IS6788A patent/IS6788A/is unknown
- 2003-04-22 BG BG107752A patent/BG107752A/bg unknown
- 2003-04-24 CR CR6963A patent/CR6963A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303341A patent/ZA200303341B/en unknown
- 2003-05-13 MA MA27158A patent/MA26960A1/fr unknown
- 2003-05-27 NO NO20032388A patent/NO325187B1/no unknown
- 2003-05-28 EC EC2003004628A patent/ECSP034628A/es unknown
-
2006
- 2006-11-13 CY CY20061101645T patent/CY1106240T1/el unknown
-
2007
- 2007-10-29 JP JP2007279951A patent/JP4971946B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020591A1 (es) | Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-[3-(4-pirrolidin-1-ilbutil) ureido] isotiazol-4-carboxilico y metodo de produccion | |
| SG11201804363UA (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
| MX2023003362A (es) | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. | |
| SG11201808220VA (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| WO2007002220A3 (en) | Aminoacetamide acyl guanidines as beta-secretase inhibitors | |
| RU97104165A (ru) | Спиро-азабициклические соединения, полезные в терапии | |
| WO2005082069A3 (en) | Hangover remedy and alcohol abatement composition | |
| SG155046A1 (en) | Process for modifying drug crystal formation | |
| RU2010107795A (ru) | Бициклические амиды для усиления глутаматергических синаптических ответов | |
| US20170349540A1 (en) | Histone deacetylase inhibitors | |
| SG11201809162XA (en) | 6-aminopyridin-3-yl thiazoles as modulators of ror?t | |
| PH12018501489A1 (en) | Compounds and compositions for the treatment of cryptosporidiosis | |
| AU2021392813A9 (en) | Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists | |
| AR112683A1 (es) | Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende | |
| MX2024000701A (es) | Metodos de tratamiento de la enfermedad de alzheimer. | |
| CA2797442A1 (en) | Process for the production of ferrous sulphate monohydrate | |
| WO2008136863A3 (en) | Synthesis of compounds useful as modulators of amyloid-beta production | |
| WO2006026204A3 (en) | Novel gamma-lactams as beta-secretase inhibitors | |
| UY29077A1 (es) | Amidas sustituidas de ácido tienopirrolcarboxílico, amidas del ácido pirrolotiazolcarboxílico y análogos relacionados como inhibidores de la caseína cinasa ie(epsilon) | |
| KR850008490A (ko) | β-락탐 항생물질의 제조방법 | |
| KR920018030A (ko) | 치환된 이미다졸-2-온의 유도체 및 이의 제조방법 | |
| PE20090192A1 (es) | Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo | |
| SG11201901954XA (en) | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof | |
| MX2022011238A (es) | Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos. | |
| HUP0004805A2 (hu) | Lényegében vízmentes habosítószer és eljárás ennek előállítására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |